Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.1.02179
European Journal of Endocrinology, Vol 155, Issue 1, 79-90
Copyright © 2006 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abs, R.
Right arrow Articles by Koltowska-Häggström, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abs, R.
Right arrow Articles by Koltowska-Häggström, M.
CLINICAL STUDY

Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults – a KIMS database analysis

Roger Abs, Ulla Feldt-Rasmussen1, Anders F Mattsson2, John P Monson3, Bengt-Åke Bengtsson4, Miklós I Góth5, Patrick Wilton2 and Maria Koltowska-Häggström2,6

Department of Endocrinology, University Hospital, Antwerp, Belgium, 1 University Hospital, Copenhagen, Denmark, 2 KIGS/KIMS/ACROSTUDY Medical Outcomes, Pfizer Endocrine Care, Sollentuna, Sweden, 3 St Bartholomew’s Hospital, London, UK, 4 Sahlgrenska University Hospital, Göteborg, Sweden, 5 National Medical Center Budapest, Hungary and 6 Department of Pharmacy, Uppsala University, Uppsala, Sweden

(Correspondence should be addressed to R Abs; Email: roger.abs{at}uza.be)

Objective: The aim of the present study was to clarify the relationship between GH deficiency (GHD) and some cardiovascular risk factors and to analyse the effect of GH replacement therapy in a large number of patients over a prolonged period of time.

Design: Data for analysis were retrieved from KIMS (Pfizer International Metabolic Database). Serum concentrations of total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides were obtained from 2589 patients at baseline and from 1206 patients after 1 and 2 years of GH replacement therapy. Body mass index (BMI), waist and hip, resting blood pressure and body composition were also measured.

Results: At baseline, the unfavourable effects of GHD were most obvious in the lipid profile demonstrating elevated mean total and LDL-cholesterol, in the increased waist circumference and the elevated BMI. The cholesterol concentration, BMI and body composition were significantly adversely affected by a number of factors, including age, sex and the use of anti-epileptic drugs. The therapeutic effect of GH was essentially uniform across the whole population. GH replacement reduced significantly the mean total and LDL-cholesterol, the waist circumference and the fat mass and was maintained during 2 years.

Conclusions: This analysis of a large number of patients confirmed that GHD adults present with an increased cardiovascular risk. The sustained improvement of the adverse lipid profile and body composition suggests that GH replacement therapy may reduce the risk of cardiovascular disease and the premature mortality seen in hypopituitary patients with untreated GHD.




This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
R. P F Dullaart, G. van den Berg, A. M van der Knaap, J. Dijck-Brouwer, G. M Dallinga-Thie, P. M J Zelissen, W. J Sluiter, and A. P van Beek
HDL cholesterol response to GH replacement is associated with common cholesteryl ester transfer protein gene variation (-629C>A) and modified by glucocorticoid treatment
Eur. J. Endocrinol., February 1, 2010; 162(2): 227 - 234.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. F. Attanasio, D. Mo, E. M. Erfurth, M. Tan, K. Y. Ho, D. Kleinberg, A. G. Zimmermann, P. Chanson, and on behalf of the International Hypopituitary Contr
Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement
J. Clin. Endocrinol. Metab., January 1, 2010; 95(1): 74 - 81.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Colao, C. Di Somma, S. Savastano, F. Rota, M. C. Savanelli, G. Aimaretti, and G. Lombardi
A Reappraisal of Diagnosing GH Deficiency in Adults: Role of Gender, Age, Waist Circumference, and Body Mass Index
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4414 - 4422.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G Brabant, E M Poll, P Jonsson, D Polydorou, and I Kreitschmann-Andermahr
Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations?
Eur. J. Endocrinol., November 1, 2009; 161(suppl_1): S25 - S31.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. D J Thomas and J. P Monson
Adult GH deficiency throughout lifetime
Eur. J. Endocrinol., November 1, 2009; 161(suppl_1): S97 - S106.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. Verhelst and R. Abs
Cardiovascular risk factors in hypopituitary GH-deficient adults
Eur. J. Endocrinol., November 1, 2009; 161(suppl_1): S41 - S49.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M Klose, B Jonsson, R Abs, V Popovic, M Koltowska-Haggstrom, B Saller, U Feldt-Rasmussen, and I Kourides
From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum - a KIMS analysis
Eur. J. Endocrinol., November 1, 2009; 161(suppl_1): S75 - S83.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. M. Webb, C. J. Strasburger, D. Mo, M. L. Hartman, S. Melmed, H. Jung, W. F. Blum, A. F. Attanasio, and on behalf of the HypoCCS International Advisory Bo
Changing Patterns of the Adult Growth Hormone Deficiency Diagnosis Documented in a Decade-Long Global Surveillance Database
J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 392 - 399.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
P. Abrams, H. Boquete, H. Fideleff, U. Feldt-Rasmussen, P. J Jonsson, M. Koltowska-Haggstrom, P. Wilton, and R. Abs
GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables
Eur. J. Endocrinol., December 1, 2008; 159(6): 825 - 832.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
F. Sen, M. Demirturk, N. Abaci, E. Golcuk, H. Oflaz, A. Elitok, F. Kutluturk, H. Issever, N. E. Unaltuna, and N. C. Ozbey
Endothelial nitric oxide synthase intron 4a/b polymorphism and early atherosclerotic changes in hypopituitary GH-deficient adult patients
Eur. J. Endocrinol., May 1, 2008; 158(5): 615 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. A van der Klaauw, N. R Biermasz, E. J M Feskens, M. B Bos, J. W A Smit, F. Roelfsema, E. P M Corssmit, H. Pijl, J. A Romijn, and A. M Pereira
The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH
Eur. J. Endocrinol., April 1, 2007; 156(4): 455 - 462.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. Rizzo, R. Trepp, K. Berneis, and E. R Christ
Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy
Eur. J. Endocrinol., March 1, 2007; 156(3): 361 - 367.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 European Society of Endocrinology.